Drax wants to feed Britain's AI habit with £20B datacenter at biomass power station

The UK's power grid capacity for data centers could become constrained, impacting availability and cost.

Drax, the operator of the UK's largest biomass power station, has announced plans to develop a £20 billion data center at its North Yorkshire site. In partnership with investment giant Brookfield and its AI infrastructure business Radiant, the project aims to provide massive computing power for the UK's burgeoning AI industry. The initial phase, planned for early 2028, would deliver 100MW of capacity with a £2.5 billion investment, potentially expanding to over 1GW. Drax claims its existing infrastructure offers advantages, including access to 4GW of grid capacity and cooling systems. The company also aims to supply up to 500MW directly from its biomass generation, subject to government approval. However, the project faces significant hurdles, including securing planning permission, regulatory approvals, commercial agreements, and, crucially, a tenant for the facility.

This proposal highlights a significant trend of established energy infrastructure pivoting to support the immense power demands of AI. Drax's ability to potentially leverage existing generation capacity and grid connections presents a competitive advantage over traditional data center developers. However, the reliance on biomass power for AI workloads introduces sustainability questions and requires specific government waivers, indicating a complex regulatory path ahead for such integrated energy-AI projects.

The venture's success hinges on securing a major tenant and navigating environmental and community concerns, which have grown increasingly vocal for large data center developments. This case exemplifies the ongoing tension between the rapid growth of AI infrastructure and the environmental and logistical challenges it presents, particularly regarding energy consumption and land use. Future AI growth may depend on creative solutions like this, but public and regulatory acceptance remains a critical factor.